Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be considered for this study if they suffer from classical or common migraine for at least 3 years.~* Candidates will recruited from the clinical case load of Dr. Zahid Bajwa and the headache and pain management center at BIDMC.~* Only patients older than 18 years of age,~* Able to communicate clearly in English,~* Able to give an informed consent will be considered as candidates.~* No limitation of gender or race is justified and thus, it is open to all patients fulfilling criteria for migraine type headache.~* Patients will be able to withdraw from the study at any time.~* They will be included in the study if they meet the criteria for migraine with or without aura (Headache-classification-committee-of-the-International-Headache-Society 1988), if they had \>4 migraine attacks each month for the previous year.~Exclusion Criteria:~* Exclusion criteria will include cardiovascular or cerebrovascular disorders,~* Cardiac risk factors and liver disease,~* Uncontrolled hypertension,~* Peripheral and central nervous system disorders that affect sensory functions (such as sensory neuropathies and chronic pain),~* The use of opiates or other analgesic drugs for any reason, and the use of other prophylactic anti-migraine drugs.~* Any patient with active hepatitis or elevated liver enzymes (based on their BIDMC medical record) will be excluded as well.~* Employees who are under the direct supervision of the investigators will not participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Maxalt administration at onset of migraine
- 2 (Type: PLACEBO_COMPARATOR): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None
- 5 (Type: EXPERIMENTAL): None
- 6 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).